Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aktis OncologyAKTS -0.91%12 3-Year EBITDA Growth Rate is -35.50% as of Jun. 2026. GuruFocus rates AKTS with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,122 Biotechnology companies, Aktis Oncology ranks worse than 92.16% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -35.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 3 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aktis Oncology was -35.50% per year. The lowest was -35.50% per year. And the median was -35.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aktis Oncology 3-Year EBITDA Growth Rate Related Terms
AKTS vs IMTX, REPL, CGEM: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Aktis Oncology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aktis Oncology 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aktis Oncology's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aktis Oncology's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -35.50% mean?
Aktis Oncology (AKTS) has a 3-Year EBITDA Growth Rate of -35.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aktis Oncology and its competitors. According to the industry distribution chart, Aktis Oncology ranks #1034 out of 1122 companies in the Biotechnology industry, placing it in the top 92.2%.
Is Aktis Oncology's 3-Year EBITDA Growth Rate too high?
Aktis Oncology's current 3-Year EBITDA Growth Rate is -35.50%. Based on the distribution chart, Aktis Oncology ranks #1034 out of 1122 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aktis Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's 3-Year EBITDA Growth Rate compare to IMTX and REPL?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #1034 out of 1122 companies for 3-Year EBITDA Growth Rate. This places Aktis Oncology in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.75, based on 1,122 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aktis Oncology and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aktis Oncology's current 3-Year EBITDA Growth Rate is -35.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current 3-Year EBITDA Growth Rate of -35.50%. The current 3-Year EBITDA Growth Rate is -35.50%. Aktis Oncology's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current 3-Year EBITDA Growth Rate is -35.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
12GF Score
Get the complete analysis for AKTS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTS has been successfully added to your 
